Free Trial

Q3 EPS Estimates for TerrAscend Raised by Seaport Res Ptn

TerrAscend logo with Medical background
Remove Ads

TerrAscend Corp. (OTCMKTS:TSNDF - Free Report) - Equities research analysts at Seaport Res Ptn lifted their Q3 2025 EPS estimates for TerrAscend in a research report issued to clients and investors on Sunday, March 9th. Seaport Res Ptn analyst S. Randhawa now expects that the company will earn ($0.03) per share for the quarter, up from their previous estimate of ($0.04). The consensus estimate for TerrAscend's current full-year earnings is ($0.14) per share. Seaport Res Ptn also issued estimates for TerrAscend's FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.13) EPS.

Separately, Atb Cap Markets cut shares of TerrAscend from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th.

Check Out Our Latest Stock Analysis on TSNDF

TerrAscend Trading Down 2.2 %

Shares of TSNDF opened at $0.44 on Wednesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.35 and a quick ratio of 0.69. The firm has a 50 day simple moving average of $0.56 and a 200-day simple moving average of $0.85. TerrAscend has a 1-year low of $0.38 and a 1-year high of $2.20. The stock has a market cap of $129.00 million, a price-to-earnings ratio of -1.57 and a beta of 1.64.

TerrAscend (OTCMKTS:TSNDF - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.04. TerrAscend had a negative net margin of 23.95% and a negative return on equity of 31.48%. The firm had revenue of $74.35 million during the quarter, compared to the consensus estimate of $72.37 million.

TerrAscend Company Profile

(Get Free Report)

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.

Featured Articles

Earnings History and Estimates for TerrAscend (OTCMKTS:TSNDF)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads

Should You Invest $1,000 in TerrAscend Right Now?

Before you consider TerrAscend, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TerrAscend wasn't on the list.

While TerrAscend currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Is There Still Money in AI? How to Invest in the Next Big Wave

Is There Still Money in AI? How to Invest in the Next Big Wave

The AI sector has taken a hit, but is the opportunity gone? Shah Gilani breaks down the current state of AI stocks and the next AI company with 10x potential.

Related Videos

Tesla Sinks on Musk Drama—Bounce or Bigger Crash?
3 AI Stocks to Watch After NVIDIA’s Dip
5 Stocks to BUY NOW in March 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads